Abstract: OBJECTIVE To explore the epidemiological characteristics of health care-associated infections (HAIs) with CRKP in hospitalized patients so as to provide bases for prevention and control of HAIs. METHODS The clinical data were retrospectively collected from 267 patients with CRKP infections who were hospitalized in Taihe Hospital Affiliated to Hubei University of Medicine from Jan. 1, 2014 to Dec. 31, 2024. The data including demographic characteristics, hospitalization stratus, distribution of departments, diagnosis and treatment procedures, infection sites, sources of specimens and result of antimicrobial susceptibility testing were extracted through electronic medical record (EMR) system, and the descriptive statistical analysis was performed. RESULTS Among the hospitalized patients with CRKP infections, the patients with no less than 60 years of age accounted for 43.45%, the proportions of the patients who received invasive procedures during the treatment process were high, the patients who received drainage tube indwelling, urinary catheterization and central venous catheterization accounted for 76.03%, 69.29% and 57.30%, respectively. Among the patients with infections, 48.69% came from neurosurgery department, and 12.36% came from cardiovascular medicine department; 74.91% had respiratory system infections. The sputum was the major specimen source, accounting for 67.42%. The result of antimicrobial susceptibility testing showed that the drug resistance rate of the CRKP strains to cephalosporins was more than 85%, while the drug resistance rates to polymyxin B and tigecycline were 3.60% and 27.27%, respectively. CONCLUSIONS The CRKP infection is highly prevalent in the advanced age patients and the patients who receive invasive procedures. The patients with the infection mainly come from neurosurgery department, and the patients with respiratory system infections are dominant. The CRKP strains show high drug resistance rates to the commonly used antibiotics such as cephalosporins and β-lactams/β-lactamase inhibitors (BLBLIs) compound preparations.